July 30, 2021 - ROSEN LOGO.jpg
RETA FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Reata Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action – RETA
15 févr. 2022 16h45 HE | The Rosen Law Firm PA
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between...
Angion_2IN-02.jpg
Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming Phase 2 Study
05 nov. 2021 00h05 HE | Angion Biomedica Corp.
UNIONDALE, N.Y., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion_2IN-02.jpg
Angion to Present Multiple Posters at Kidney Week 2021
18 oct. 2021 16h05 HE | Angion Biomedica Corp.
UNIONDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Retrophin Logo.jpg
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019
11 oct. 2019 16h05 HE | Retrophin, Inc.
SAN DIEGO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on quality of...
Reaching underserved
Reaching underserved patients in the kidney community: American Kidney Fund expands online resources for rare diseases
06 sept. 2018 11h30 HE | American Kidney Fund
ROCKVILLE, Md., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Because many relatively unknown rare diseases can cause permanent damage to the kidneys, the American Kidney Fund (AKF) today announced it has...